NCT00322127View on ClinicalTrials.gov

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 14, 2006

Primary Completion Date

January 23, 2015

Study Completion Date

January 23, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

AMD3100

a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00322127 - An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers | Biotech Hunter | Biotech Hunter